Insulinoma laboratory tests: Difference between revisions
No edit summary |
(Mahshid) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 14: | Line 14: | ||
** Serum [[proinsulin]] ≥ 22 pmol/L | ** Serum [[proinsulin]] ≥ 22 pmol/L | ||
*Patients with insulinoma may have elevated [[insulin]] to [[glucose]] ratio of > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test. It is a [[Gold standard (test)|gold standard test]]. <ref name="pmid18672144">{{cite journal| author=Callender GG, Rich TA, Perrier ND| title=Multiple endocrine neoplasia syndromes. | journal=Surg Clin North Am | year= 2008 | volume= 88 | issue= 4 | pages= 863-95, viii | pmid=18672144 | doi=10.1016/j.suc.2008.05.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18672144 }} </ref> | *Patients with insulinoma may have elevated [[insulin]] to [[glucose]] ratio of > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test. It is a [[Gold standard (test)|gold standard test]]. <ref name="pmid18672144">{{cite journal| author=Callender GG, Rich TA, Perrier ND| title=Multiple endocrine neoplasia syndromes. | journal=Surg Clin North Am | year= 2008 | volume= 88 | issue= 4 | pages= 863-95, viii | pmid=18672144 | doi=10.1016/j.suc.2008.05.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18672144 }} </ref> | ||
**33% patients | **33% patients develop clinical [[symptoms]] within 12 hours of the fasting | ||
**80% develop within 24 hours of the fasting | **80% develop clinical [[symptoms]] within 24 hours of the fasting | ||
**90% develop within 48 hours of the fasting | **90% develop clinical [[symptoms]] within 48 hours of the fasting | ||
**100% develop within 72 hours of the fasting | **100% develop clinical [[symptoms]] within 72 hours of the fasting | ||
==References== | ==References== | ||
| Line 28: | Line 28: | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:06, 27 November 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Insulinoma laboratory tests |
|
Risk calculators and risk factors for Insulinoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Laboratory findings consistent with the diagnosis of insulinoma include serum glucose < 55 mg/dL, serum Insulin > 5-10 μU/mL, serum C-Peptide > 200 pmol/L, and serum proinsulin ≥ 22 pmol/L. Patients with insulinoma may have elevated insulin to glucose ratio of > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test(gold standard test). 33% patients have clinical symptoms within 12 hours of the fasting, 80% develop within 24 hours, 90% develop within 48 hours, and 100% develop within 72 hours.
Laboratory Findings
- Laboratory findings consistent with the diagnosis of insulinoma include:[1]
- Serum glucose < 55 mg/dL
- Serum Insulin > 5-10 μU/mL
- Serum C-Peptide > 200 pmol/L
- Serum proinsulin ≥ 22 pmol/L
- Patients with insulinoma may have elevated insulin to glucose ratio of > 0.4, which is usually suggestive of insulinoma after a 72-hour fast test. It is a gold standard test. [2]
References
- ↑ Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
- ↑ Callender GG, Rich TA, Perrier ND (2008). "Multiple endocrine neoplasia syndromes". Surg Clin North Am. 88 (4): 863–95, viii. doi:10.1016/j.suc.2008.05.001. PMID 18672144.